Brief: Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III Maveric Trial In Recurrent Pericarditis
16/04/2025 13:20
April 16 (Reuters) - Cardiol Therapeutics Inc CRDL.TO: CARDIOL THERAPEUTICS ENROLLS FIRST PATIENT IN PIVOTAL PHASE III MAVERIC TRIAL IN RECURRENT PERICARDITIS Source text: [ID:n0001062993-25-007566] Further company coverage: CRDL.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM